

Iris Grossman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9989884/publications.pdf>

Version: 2024-02-01

34
papers

1,116
citations

361413

20
h-index

477307

29
g-index

37
all docs

37
docs citations

37
times ranked

1731
citing authors

#	ARTICLE	IF	CITATIONS
1	Discovery and Targeting of the Signaling Controls of PNPLA3 to Effectively Reduce Transcription, Expression, and Function in Pre-Clinical NAFLD/NASH Settings. <i>Cells</i> , 2020, 9, 2247.	4.1	26
2	Characterizing patient compliance over six months in remote digital trials of Parkinsonâ€™s and Huntington disease. <i>BMC Medical Informatics and Decision Making</i> , 2018, 18, 138.	3.0	26
3	Large-scale transcriptomic analysis reveals that pridopidine reverses aberrant gene expression and activates neuroprotective pathways in the YAC128 HD mouse. <i>Molecular Neurodegeneration</i> , 2018, 13, 25.	10.8	26
4	Pharmacogenomics strategies to optimize treatments for multiple sclerosis: Insights from clinical research. <i>Progress in Neurobiology</i> , 2017, 152, 114-130.	5.7	29
5	A pharmacogenetic signature of high response to Copaxone in late-phase clinical-trial cohorts of multiple sclerosis. <i>Genome Medicine</i> , 2017, 9, 50.	8.2	25
6	The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease. <i>Neurobiology of Disease</i> , 2017, 97, 46-59.	4.4	105
7	Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation <i>in vivo</i> in a mouse model. <i>Annals of the New York Academy of Sciences</i> , 2017, 1407, 75-89.	3.8	7
8	Biobanking in Israel 2016â€“17; expressed perceptions versus real life enrollment. <i>BMC Medical Ethics</i> , 2017, 18, 63.	2.4	1
9	Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. <i>JCI Insight</i> , 2017, 2, .	5.0	39
10	Dopamine D2 receptor gene variants and response to rasagiline in early Parkinsonâ€™s disease: a pharmacogenetic study. <i>Brain</i> , 2016, 139, 2050-2062.	7.6	53
11	Functional effects of the antigen glatiramer acetate are complex and tightly associated with its composition. <i>Journal of Neuroimmunology</i> , 2016, 290, 84-95.	2.3	21
12	Laquinimod arrests experimental autoimmune encephalomyelitis by activating the aryl hydrocarbon receptor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6145-E6152.	7.1	111
13	Pridopidine activates neuroprotective pathways impaired in Huntington Disease. <i>Human Molecular Genetics</i> , 2016, 25, 3975-3987.	2.9	65
14	Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids. <i>Scientific Reports</i> , 2015, 5, 10191.	3.3	14
15	Roadmap to Drug Development Enabled by Pharmacogenetics. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2015, , 43-67.	0.6	1
16	<i>TOMM40</i> and <i>APOE</i> : Requirements for replication studies of association with age of disease onset and enrichment of a clinical trial. <i>Alzheimer's and Dementia</i> , 2013, 9, 132-136.	0.8	59
17	Clinical Trials of AD Delay of Onset: Enrichment by a Prognostic Genetic Biomarker. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2013, , 141-160.	0.6	0
18	Characterization of the Poly-T Variant in the TOMM40 Gene in Diverse Populations. <i>PLoS ONE</i> , 2012, 7, e30994.	2.5	47

#	ARTICLE	IF	CITATIONS
19	Multiple sclerosis pharmacogenetics: personalized approach towards tailored therapeutics. EPMA Journal, 2010, 1, 317-327.	6.1	8
20	Alzheimer's disease: diagnostics, prognostics and the road to prevention. EPMA Journal, 2010, 1, 293-303.	6.1	36
21	Healthy aging and preclinical dementia: The United States-Israel Longitudinal Database Project. , 2010, 6, 475-481.		5
22	Pharmacogenetics and Pharmacogenomics. , 2010, , 175-190.		3
23	Pharmacogenetics and Pharmacogenomics. , 2009, , 321-334.		0
24	Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis. European Journal of Human Genetics, 2009, 17, 946-957.	2.8	89
25	ADME pharmacogenetics: current practices and future outlook. Expert Opinion on Drug Metabolism and Toxicology, 2009, 5, 449-462.	3.3	25
26	Pipeline Pharmacogenetics: A Novel Approach to Integrating Pharmacogenetics into Drug Development. Current Pharmaceutical Design, 2009, 15, 3754-3763.	1.9	9
27	Cytochrome P450 testing in the treatment of depression. , 2009, , 597-619.		0
28	Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes. Pharmacogenomics, 2008, 9, 847-868.	1.3	33
29	Genetic determinants of variable metabolism have little impact on the clinical use of leading antipsychotics in the CATIE study. Genetics in Medicine, 2008, 10, 720-729.	2.4	48
30	Routine pharmacogenetic testing in clinical practice: dream or reality?. Pharmacogenomics, 2007, 8, 1449-1459.	1.3	43
31	Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors. Genetics in Medicine, 2007, 9, 826-835.	2.4	56
32	Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers. Pharmacogenetics and Genomics, 2007, 17, 657-666.	1.5	74
33	Testing for cytochrome P450 polymorphisms in adults with non-psychotic depression treated with selective serotonin reuptake inhibitors (SSRIs). Evidence Report/technology Assessment, 2007, , 1-77.	1.3	21
34	Trick or treat: The effect of placebo on the power of pharmacogenetic association studies. Human Genomics, 2005, 2, 28.	2.9	10